Mesothelioma Gene Therapy Trial Shows ‘Real Potential’

Research & Clinical Trials
Reading Time: 4 mins
Publication Date: 02/17/2020
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Lashawn
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite Asbestos.com’s Article

APA

Povtak, T. (2020, November 3). Mesothelioma Gene Therapy Trial Shows ‘Real Potential’. Asbestos.com. Retrieved December 3, 2022, from https://www.asbestos.com/news/2020/02/17/gene-therapy-potential-mesothelioma/

MLA

Povtak, Tim. "Mesothelioma Gene Therapy Trial Shows ‘Real Potential’." Asbestos.com, 3 Nov 2020, https://www.asbestos.com/news/2020/02/17/gene-therapy-potential-mesothelioma/.

Chicago

Povtak, Tim. "Mesothelioma Gene Therapy Trial Shows ‘Real Potential’." Asbestos.com. Last modified November 3, 2020. https://www.asbestos.com/news/2020/02/17/gene-therapy-potential-mesothelioma/.

Gene editing and gene therapy

Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial.

The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively.

Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy.

“This is a very interesting concept,” oncologist Dr. Bernardo Goulart of the Seattle Cancer Care Alliance, told The Mesothelioma Center at Asbestos.com. “There is real potential here. We are excited about moving it forward.”

20 Years in the Making for Gene Therapy

Scientists have worked for more than 20 years to fine-tune gene therapy and make it an effective treatment for mesothelioma.

Success at the phase III level — increasing survival rates — could signal the culmination of decades of development.

“The goal here is to get definitive answers, not a suggestion, as to whether the new treatment is better than [current] standard of care,” said pulmonary oncologist Dr. Dan Sterman at New York University Langone Medical Center. “The hope is we may have a new treatment option.”

Standard of care today remains a combination of chemotherapy, radiation and resection, which has not been effective overall.

Less than a third of the patients with the disease qualify for the surgical option.

Sterman has been a longtime pioneer in the development of gene therapy for mesothelioma, stemming from his years at the University of Pennsylvania Abramson Cancer Center.

Shot of a young scientist using a microscope while conducting research in a laboratory
Clinical Trials for Mesothelioma Patients
Get help improving your prognosis by finding a mesothelioma clinical trial today.

Modified Virus Triggers Anti-Tumor Response

The investigational drug is a genetically engineered adenovirus that triggers the anti-tumor effects of interferon, a naturally occurring protein that destroys tumor cells.

It is injected directly into the pleural space through a catheter and works by helping the body produce more of the protein.

The official name of the therapy is Adenovirus-Delivered Interferon Alpha-2b, often referred to as rAd-IFN.

“We’re hoping the triple-drug combination will demonstrate a significant improvement in survival well beyond standard-of-care treatment,” Sterman said.

Investigators are hoping to enroll at least 300 patients through more than a dozen sites.

Lead investigators and sites in the U.S. already include:

  • Dr. Robert Cameron, UCLA Medical Center
  • Dr. Corey Langer, University of Pennsylvania
  • Dr. Tobias Peikert, Mayo Clinic Minnesota
  • Dr. Daniel Sterman, NYU Clinical Cancer Center
  • Dr. Chao Huang, University of Kansas Medical Center
  • Dr. Joseph Friedberg, University of Maryland Medical Center
  • Dr. Robert Kratzke, Masonic Cancer Center, University of Minnesota
  • Dr. Jonathan Dowell, University of Texas Southwestern Medical Center
  • Dr. David Feller-Kopman, Johns Hopkins Kimmel Comprehensive Cancer Center
  • Dr. Tawee Tanvetyanon, Moffitt Cancer Center

The Seattle Cancer Care Alliance, with Goulart as the investigator, is one of a few more sites expected to begin accepting patients for the trial in the coming weeks.

Patients also are being accepted at centers in Poland, Germany, Australia, France and the United Kingdom. Trizell, a gene therapy company with facilities in the UK and Finland, is sponsoring the clinical trial.

Who Qualifies for the INFINITE Clinical Trial?

To qualify for the INFINITE clinical trial, mesothelioma patients must have already failed a minimum of one and a maximum of two treatment regimens.

Enrollees will be randomized 1-1 for the gene therapy treatment or the control group, which will allow investigators to compare the effectiveness of the treatment.

The gene therapy drug will be given only once, delivered directly into the pleural cavity.

Both groups will receive the celecoxib and gemcitabine.

The celecoxib is given orally twice daily for the first 14 days of the study. Gemcitabine will be given intravenously on days first and eighth day of a repeating three-week cycle until disease progression or withdrawal from the study.

Following Earlier Success

One reason for the optimism going into phase III was the success in earlier phases. In one phase II trial, the disease control rate was 87.5% for patients who either had failed standard chemotherapy or were newly diagnosed.

Among those using it as second-line treatment, there was a three-year survival rate of 20% and a median survival of 17 months.

“A phase III trial gives us the possibility of having another important drug in our armamentarium with potentially proven benefits,” Sterman said.

Connect with a Mesothelioma Doctor
Find a Top Specialist Near You